Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Nvidia Options Price in $280 Billion Earnings Swing 
Tesla Raises Cybertruck Prices by $5,000 in US 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
SK Hynix Shares Fall as Workers Reject Wage Deal 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Trump Buys SpaceX Shares After Record IPO 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Add as a preferred source on Google
MALVERN, Pa., April 19, 2018 -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2018 earnings on Wednesday, April 25 at 4:00 PM Eastern Time.
The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Wednesday, April 25, 2018. The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com. If you are unable to participate during the live webcast, an archive will be available on our website for two weeks.
About BioTelemetry
BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The Company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services. More information can be found at www.gobio.com.
Contact:
BioTelemetry, Inc.
Heather C. Getz
Investor Relations
800-908-7103
[email protected]
